Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Healthcare Triangle (HCTI) Gains from Sales and Divestitures (2023 - 2025)

Healthcare Triangle's Gains from Sales and Divestitures history spans 3 years, with the latest figure at $583000.0 for Q3 2025.

  • For Q3 2025, Gains from Sales and Divestitures changed 0.0% year-over-year to $583000.0; the TTM value through Sep 2025 reached $583000.0, changed 0.0%, while the annual FY2024 figure was $193451.0, 58.63% up from the prior year.
  • Gains from Sales and Divestitures for Q3 2025 was $583000.0 at Healthcare Triangle, down from $1.5 million in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $1.5 million in Q2 2025 and bottomed at $48363.0 in Q1 2024.
  • The 3-year median for Gains from Sales and Divestitures is $157701.5 (2023), against an average of $391084.5.
  • The largest YoY upside for Gains from Sales and Divestitures was 1403.03% in 2025 against a maximum downside of 0.0% in 2025.
  • A 3-year view of Gains from Sales and Divestitures shows it stood at $121952.0 in 2023, then soared by 58.63% to $193451.0 in 2024, then surged by 201.37% to $583000.0 in 2025.
  • Per Business Quant, the three most recent readings for HCTI's Gains from Sales and Divestitures are $583000.0 (Q3 2025), $1.5 million (Q2 2025), and $48363.0 (Q1 2025).